Latanoprost Ophthalmic

Introduction Overview

Generic Name

latanoprost ophthalmic

Brand Name

Xelpros

Dosage Form

ophthalmic solution (eye drops)

Drug Class

ophthalmic glaucoma agents

Pharmacokinetics

Absorption:
Latanoprost ophthalmic solution is applied topically to the eye, where it is readily absorbed through the cornea into the aqueous humor. After ocular administration, latanoprost is rapidly hydrolyzed by corneal esterases to its active form, latanoprost acid, which is responsible for its pharmacologic effects. Systemic absorption following ocular administration is minimal due to the local route, limiting systemic exposure and potential systemic adverse effects. Studies indicate that peak plasma concentrations of latanoprost acid are low, typically occurring within 5 minutes post administration, and decrease rapidly thereafter.

Distribution:
Once converted to latanoprost acid, the compound distributes primarily to ocular tissues involved in aqueous humor dynamics, including the ciliary body and trabecular meshwork. The intraocular penetration enables latanoprost acid to exert its pharmacologic effect by interacting with prostanoid receptors. Systemic distribution is limited, but latanoprost acid can be distributed throughout the body if absorbed into systemic circulation, binding moderately to plasma proteins. Due to the localized administration and rapid metabolism, systemic concentrations remain low, minimizing systemic exposure.

Metabolism:
Latanoprost is a prodrug metabolized rapidly by esterases present in the cornea to latanoprost acid, the pharmacologically active free acid. Once in systemic circulation, latanoprost acid undergoes further metabolism predominantly by beta-oxidation, which produces inactive metabolites. These metabolites are conjugated (e.g., glucuronidation) and subsequently eliminated. The metabolic pathways are primarily hepatic, involving enzymes that contribute to prostaglandin catabolism.

Elimination:
The inactive metabolites of latanoprost acid are excreted mainly via the renal route. The elimination half-life of latanoprost acid from plasma is brief, approximately 17 minutes, indicating rapid clearance. Because the dosing is local and the systemic concentrations are low, accumulation is minimal with once-daily dosing. The rapid elimination of metabolites helps reduce systemic side effects and contributes to the drug’s favorable safety profile in ophthalmic use.

Dosage Forms

Available Dosage Forms:
Xelpros is supplied as an ophthalmic solution formulated as eye drops intended for topical ocular administration. The product is preservative-free, utilizing potassium sorbate as the preservative system instead of benzalkonium chloride, a common preservative in other latanoprost formulations. This formulation is notable because it reduces ocular surface irritation commonly attributed to benzalkonium chloride. Xelpros comes in single-use containers to maintain sterility and facilitate ease of use.

Dosages for Adults and Adolescents:
The standard recommended dose of Xelpros in adults is one drop applied to the affected eye(s) once daily in the evening. This dosing regimen leverages the drug’s 24-hour intraocular pressure-lowering effect and minimizes systemic exposure. The once-daily evening administration allows for optimal efficacy and tolerability. There is no recommendation for pediatric use due to insufficient data.

Specific Patient Populations:
For patients who wear soft contact lenses, it is advised not to use Xelpros while wearing lenses due to the potential for the drug to interact with contact lens materials. Contact lenses should be removed prior to administration and may be reinserted 15 minutes after dosing. The preservative-free formulation is particularly beneficial for patients with ocular surface disease or sensitivity to preservatives, as it reduces the risk of irritation. Special caution is advised in patients with a history of ocular herpes simplex infection, retinal detachment, or recent ocular surgery. Safety and efficacy have not been established in pediatric populations or pregnant women; therefore, clinical judgment is essential in these cases.

Mechanism Of Action

Latanoprost, the active component of Xelpros, is a synthetic prostaglandin F2-alpha analog. After topical ocular administration, latanoprost is enzymatically hydrolyzed to its active free acid form in the cornea. This active metabolite exerts its primary pharmacologic action by selectively binding to prostanoid FP receptors located in the ciliary muscle of the eye.

Activation of FP receptors leads to remodeling of the extracellular matrix within the uveoscleral pathway, resulting in increased uveoscleral outflow of aqueous humor. This enhanced outflow effectively reduces intraocular pressure (IOP), a critical factor in the pathophysiology of glaucoma and ocular hypertension. Unlike other hypotensive agents that reduce aqueous humor production, latanoprost primarily augments drainage through the unconventional outflow route.

Cellularly, latanoprost’s binding to the FP receptor activates intracellular signaling cascades involving phosphatidylinositol breakdown and increased intracellular calcium, which remodel the extracellular matrix by upregulating matrix metalloproteinases. This process decreases resistance in the uveoscleral pathway. Clinically, lowering IOP helps prevent glaucomatous optic nerve damage and associated visual field loss.

Comparatively, latanoprost shares its mechanism with other prostaglandin analogs like travoprost and bimatoprost but is distinguished by its pharmacokinetic properties and formulation, such as the preservative-free nature of Xelpros. Clinical trials demonstrate that latanoprost effectively reduces IOP with a favorable safety profile, confirming this mechanism's translation into therapeutic benefit for glaucoma patients.

Pharmacological Actions

Potent selective agonist of prostanoid FP receptors in the eye.
Enhances uveoscleral outflow of aqueous humor, lowering intraocular pressure.
Exerts minimal effect on aqueous humor production.
Remodels extracellular matrix in ciliary muscle by upregulating matrix metalloproteinases.
Reduces intraocular pressure to prevent optic nerve damage in glaucoma.
Provides 24-hour IOP control with once-daily dosing.
Locally acting with minimal systemic absorption and side effects.
Improves ocular hypertension management in open-angle glaucoma cases.
Preservative-free formulation reduces ocular surface irritation compared to BAK-containing drops.
Induces changes in periorbital pigmentation due to increased melanin production.
Stimulates eyelash growth and thickening as a side effect.
Demonstrates neuroprotective potential in preclinical ocular models.
Compatible with other glaucoma medications under monitored use.
Exhibits rapid conversion from prodrug to active metabolite in ocular tissues.
Stable at room temperature after opening, providing convenience in use.

Therapeutic Or Clinical Uses

Treatment of elevated intraocular pressure in patients with open-angle glaucoma.
Management of ocular hypertension to prevent optic nerve damage.
Used in adult patients to reduce the risk of glaucoma progression.
Adjunctive therapy in combination with other glaucoma agents if monotherapy insufficient.
Preventive lowering of intraocular pressure after ocular surgery in glaucoma patients.
Management of cases where patients have sensitivities to preservatives in other eye drops.
Reduction of risk for vision loss associated with glaucoma progression.
Preferred choice for patients requiring once-daily glaucoma treatment for improved adherence.
Alternative for patients who do not tolerate other prostaglandin analogs due to preservatives.
Utility in patients at high risk of glaucomatous optic neuropathy.
Adjustment therapy in cases of previous inadequate response to beta-blockers or carbonic anhydrase inhibitors.
Therapeutic modification of ocular pigmentation changes in clinical monitoring.
Off-label uses include ocular hypertension associated with secondary glaucoma types under specialist supervision.
Considered first-line treatment for primary open-angle glaucoma by many ophthalmologists.
Administered to reduce IOP before and after ocular surgeries involving intraocular pressure risks.

Side Or Adverse Effects

Gradual increase in brown pigmentation of the iris, eyelids, and eyelashes.
Possible thickening of eyelashes (hypertrichosis).
Ocular irritation including stinging, burning, or redness immediately after application.
Eye watering and itching sensation.
Blurred vision or visual disturbances following instillation.
Foreign body sensation or feeling of something in the eye.
Increased sensitivity to light (photophobia).
Eyelid edema or puffiness.
Rare but serious allergic reactions including hives, swelling of face or throat, difficulty breathing.
Signs of ocular infection, such as redness, swelling, crusting, or discharge.
Eye discomfort or severe pain necessitating discontinuation.
Potential for exacerbation of ocular herpes simplex infections.
Possible retinal detachment or complications in patients with pre-existing retinal conditions.
Transient hyperemia of the conjunctiva.
Rare systemic effects are uncommon due to minimal systemic absorption.

Precautions

Avoid use in patients with known hypersensitivity to latanoprost or any components, including preservatives such as potassium sorbate.
Not recommended for use in patients with active ocular infections, including herpes simplex keratitis.
Use with caution in patients with a history of retinal detachment or uveitis.
Advise patients to remove contact lenses prior to administration and wait at least 15 minutes before reinsertion.
Monitor patients for any changes in iris pigmentation which may be permanent.
Caution advised during pregnancy; risk to the fetus is unclear.
Breastfeeding safety has not been well established; weigh risks and benefits.
Avoid concurrent use with other prostaglandin analogs or ocular hypotensive agents unless directed by a healthcare provider.
Store unopened bottles in the refrigerator; after opening, store at room temperature and discard per instructions.
Ensure aseptic technique to prevent contamination of the dropper tip to avoid eye infections.
Advise patients not to double dose if a dose is missed; apply the next dose as scheduled.
Advise to avoid wearing soft contact lenses during treatment due to potential for lens discoloration or damage.
Regular ocular examination is recommended to monitor intraocular pressure and ocular health.
Be alert for signs of ocular inflammation or allergic reaction that require prompt medical attention.
Use with caution in patients with compromised ocular surfaces or dry eyes.

Warnings

May cause permanent changes in iris pigmentation; inform patients that eye color changes can take months or years to develop and may be irreversible.
Discontinue use immediately and seek medical care if signs of severe eye infection or allergy develop, including swelling, redness, pain, or vision changes.
Avoid contamination of the dropper tip to prevent serious ocular infections.
Use caution in patients with active intraocular inflammation or uveitis, as latanoprost can exacerbate these conditions.
Not to be used in the presence of known hypersensitivity to latanoprost or any formulation components.
May increase pigmentation around the eye and eyelash growth, which could cause cosmetic asymmetry if only one eye is treated.
Use with caution in patients with a history of herpetic eye disease, as it may trigger recurrence.
Patients should be warned about the risk of increased iris pigmentation potentially leading to permanent heterochromia.
Avoid simultaneous use with other prostaglandin analogs to prevent additive side effects.
Patients should notify healthcare providers of any ocular surgery or injury, as latanoprost may affect healing.
Store and handle according to instructions to maintain drug stability and efficacy.
Exercise caution when prescribing to pregnant or nursing women due to insufficient safety data.
Patients should avoid driving or operating machinery until they know how the medication affects their vision.
Do not use after the expiration date or if the solution changes color or clarity.
Advise patients about the proper technique for administration to reduce risk of overdose or contamination.

Contraindication

Known hypersensitivity to latanoprost or any ingredients of the formulation including potassium sorbate.
History of hypersensitivity or allergic reaction to prostaglandin analogs.
Presence of active ocular infections including bacterial, fungal, or viral keratitis, especially herpes simplex keratitis.
Patients with previous hypersensitivity reactions to Xelpros or other latanoprost-containing preparations.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Contraindicated in patients with unexplained eye pain, redness, or visual disturbances without prior ophthalmic evaluation.
Avoid use in patients with active or history of inflammation of the anterior segment of the eye (uveitis).
Not intended for systemic use or other off-label routes of administration.
Contraindicated in case of severe ocular surface disease where drop formulation may exacerbate condition.
Avoid use if eye drop bottle or solution is contaminated or compromised.
Contraindicated in patients who have previously exhibited signs of ocular surface toxicity from other eye medications.
Do not use in presence of retinal detachment or advanced glaucoma without specialist supervision.
Avoid use in patients allergic to preservatives of the formulation, although Xelpros is preservative-free except potassium sorbate.
Avoid use in patients who cannot comply with proper administration instructions as misuse may cause harm.
Do not combine with other prostaglandin receptor agonists unless specifically advised by a healthcare professional.

Drug Interactions

Concurrent use with other prostaglandin analogs may increase the risk of additive ocular side effects and is generally not recommended.
Co-administration with topical beta-blockers or carbonic anhydrase inhibitors is common and generally safe but should be monitored for additive intraocular pressure lowering.
Use caution with medications that may cause ocular irritation or dryness, as combined effects may exacerbate discomfort.
Systemic drug interactions are minimal due to low systemic absorption of latanoprost ophthalmic solution.
Use with preservative-containing eye drops may increase risk of ocular surface toxicity, although Xelpros is preservative-free.
No significant pharmacokinetic interactions with commonly used systemic drugs have been reported.
Medications affecting prostaglandin metabolism or signaling pathways may theoretically alter efficacy but clinical implications are unknown.
Patients using multiple ocular medications should separate administrations by at least 5 minutes to avoid dilution or washout.
Use caution when combining with ocular medications known to affect iris pigmentation or eyelash growth to monitor for additive changes.
Interactions with systemic NSAIDs or corticosteroids have not shown clinically significant effects on latanoprost efficacy.
Limited data on interaction with systemic antihypertensive agents suggest no meaningful impact on blood pressure control.
Use caution when combining with other ocular hypotensive agents to avoid excessive lowering of intraocular pressure.
Potential interactions with contact lens cleaning solutions are not expected but lenses should be removed before administration.
Patients should inform healthcare providers about all concomitant medications including over-the-counter and herbal supplements.
Use of latanoprost with CYP450 enzyme inducers or inhibitors is unlikely to affect ocular pharmacodynamics due to local application.

Preparations Of The Drug

Xelpros ophthalmic solution 0.005% (50 mcg/mL) latanoprost in a preservative-free formulation using potassium sorbate.
Single-use vials to maintain sterility of preservative-free eye drops and enhance patient safety.
Packaged in sterile plastic containers designed for precise dosing and ease of use.
Formulated to be free of benzalkonium chloride (BAK), reducing ocular surface irritation associated with preservatives.
Available in multi-vial packaging sets suitable for a 30-day treatment course, with each vial intended for single use and immediate disposal after opening.
Stable when unopened at refrigerated temperatures, and stable at room temperature after opening for the period indicated in the product instructions.
Clear, colorless to pale yellow transparent solution with isotonic pH optimized for ocular tolerance.
Manufactured to provide once-daily dosing convenience with consistent release and bioavailability of the active component.
Includes instructions for proper storage, handling, administration technique, and single-use vial disposal.
Designed to minimize contamination risk with a sterile tip and single-use vial format.
Compatible with other commonly used ophthalmic drug formulations when administered separately with time intervals.
Packaging complies with regulatory standards for ophthalmic sterile products, including tamper evidence.
No added preservatives ensures suitability for glaucoma patients sensitive to chemical irritants.
Includes patient education materials emphasizing safe administration, storage, and avoiding contamination.
Formulated for adults requiring chronic intraocular pressure management with improved ocular surface tolerability.